Clinical Trials Browser

Leukemia, Myeloid, Acute × entrectinib × 1 year × Clear all

NCT05396859 2026-04-27

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute